Physician profile
Hannah Wilkinson
NPI 1023867447
$2,772.36
in general payments reported to CMS, 2019-2025
18 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $283 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Travel and Lodging: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.81 |
| Travel and Lodging | $291.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $786.46 | 2025 | Ha Minuteman G3-R |
| Globus Medical, INC. | $732.93 | 2025 | Senza, Vyrsa V1 |
| Biotronik Nro, INC. | $399.40 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $241.17 | 2024-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.58 | 2024-2025 | Relistor |
| Lilly USA, LLC | $83.37 | 2024-2025 | Amyvid, Kisunla, Reyvow |
| Valinor Pharma, LLC | $71.79 | 2024-2025 | Movantik |
| Pfizer INC. | $67.19 | 2024-2025 | |
| Abbvie INC. | $46.55 | 2025 | |
| Virtus Pharmaceuticals LLC | $43.95 | 2025 | Levorphanol Tartrate |
| Lundbeck LLC | $43.86 | 2025 | Vyepti |
| Bioventus LLC | $43.65 | 2024-2025 | Xcell, Durolane |
| Sk Life Science, INC. | $32.44 | 2025 | |
| Janssen Biotech, INC. | $25.00 | 2025 | |
| Boston Scientific Corporation | $21.01 | 2025 | Wavewriter Alpha Prime 16 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $19.22 | 2024 | Vyvgart Hytrulo |
| Vertex Pharmaceuticals Incorporated | $14.72 | 2025 | |
| Glaxosmithkline, LLC. | $14.07 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.